MiR-326 down-regulated the external secretion of TGF-β1 via the SMO/Gli2 pathway instead of by targeting the 3′-UTR of TGF-β1 in the glioma cells, and this resulted in a reversal of the glioblastoma-associated immunosuppressive environment. Here, SMO is linked to glioma.